An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.
Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…
Summary: In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of…
An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.
A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.